Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

Table 2 Disease characteristics at baseline. Categorical data are shown by N (%), metric data by µ ± SD. Percentages may not sum up to 100% in case of missing data

Parameter	Switch (N = 153)
Migraine Classification
CM	73 (47.7%)
EM	80 (52.3%)
High Frequency EM^a	57 (37.3%)
Low Frequency EM^a	23 (15.0%)
Number of migraine days in 28 days prior to first dose
Total	13.6 ± 6.5
CM	17.7 ± 6.2
EM	9.9 ± 4.1

^aEM patients with ≥ 8 days during the 28 days baseline period were regarded as “high frequency”, < 8 days as “low frequency”

ISSN: 1129-2377